<DOC>
	<DOCNO>NCT00150436</DOCNO>
	<brief_summary>To evaluate long-term safety efficacy pregabalin patient postherpetic neuralgia .</brief_summary>
	<brief_title>To Evaluate Long-Term Safety Efficacy Pregabalin Patients With Postherpetic Neuralgia .</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Must meet inclusion criterion precede doubleblind BID study postherpetic neuralgia Must receive pregabalin/placebo doubleblind condition minimum 3 week . Patients participate experience serious adverse event precede doubleblind BID study determine related study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>